Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 181,601 shares at $0.97 ($169K) on 2025-12-04, disclosed to the SEC on 2025-12-04.
Scheduled sale ($169k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.89 | 38,043 | $34K | 20.0% |
| 2 | $0.87 | 36,726 | $32K | 18.9% |
| 3 | $0.97 | 53,416 | $52K | 30.6% |
| 4 | $0.97 | 53,416 | $52K | 30.6% |
| Total | $0.93 avg | 181,601 | $169K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |